Big Pharma-backed Sitryx locks an additional $39M in a Series A raise to advance its immunometabolic pipeline

Sitryx Therapeutics has raised an additional £32 million ($39 million) in a follow-on to its 2018 Series A to help push its immunometabolic pipeline into the clinic.

New investor Oxford Science Enterprises (OSE) joins the fray with Big Pharma backers GSK and Eli Lilly, as well as Sofinnova Partners, SV Health Investors and Longwood Fund. The Oxford, UK-based company made its debut in 2018 with a $30 million Series A, bringing its total fundraising to more than $75 million.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

At-Home Electrical Stimulation Fails to Treat Major Depressive Episodes

Unsupervised, at-home use of transcranial direct current stimulation (tDCS) was no better than a sham control for treating a major depressive episode, a randomized trial

January 4, 2024

Out-of-pocket costs from diagnostic testing after prostate cancer screening are common and rising

Prostate-specific antigen (PSA) screening aims to identify men who may harbor potentially lethal prostate cancer, and those with high PSA results often require more extensive

July 15, 2024

With Covid sales declining, Pfizer zeroes in on M&A and oncology

Roughly a month after announcing plans to merge several units under Sumitomo Pharma America this July, the drugmaker is making cuts in Massachusetts. Sumitomo Pharma

May 3, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.